45 results about "Bronchitic asthma" patented technology

The invention relates to a nitric oxide data analysis method and system for bronchial asthma assessment. According to the method, exhaled air nitric oxide and pulmonary alveolar nitric oxide of a patient, omics data and clinical information are acquired in a standardized manner, and multi-dimensional features are constructed after data cleaning and fusion; comprise an inflammation level index, an inflammation region entropy, an inflammation synergy index, a glucocorticoid response factor, an infection-smoking synergy influence factor and a heredity-symptom distribution index. And outputting initial risk assessment based on an explainable elevator EBM model, and finally generating an asthma risk probability through a weighted integration formula to realize three-level layering: low / medium / high risk. The system dynamically associates treatment decisions, for example, the drug dosage and the monitoring frequency are improved when the risk is upgraded, and the medication scheme is optimized when the risk is degraded. According to the scheme, the limitation of traditional single marker static analysis is broken through, multiple mechanisms of dissection, immunity and pharmacology are fused, the evaluation precision and clinical applicability are remarkably improved, the acute attack rate is reduced, and accurate typing treatment is guided.

The invention provides a cough and asthma relieving compound medicine for nebulization treatment of a respiratory system as well as preparation and application of the cough and asthma relieving compound medicine. The cough and asthma relieving compound medicine takes various traditional Chinese medicinal materials such as ginkgo and ephedra as main raw materials, and further comprises compound bacteria, an osmotic pressure regulator and a cosolvent. The compound bacteria are prepared from cordyceps sinensis, bamboo fungus and pine olive in a specific mass ratio, the osmotic pressure regulator is prepared from glucose and glycerol in a specific ratio, and the cosolvent has multiple selectable components. The preparation method comprises a plurality of steps and unique processes including medicinal material extraction, salifying modification, ultrasonic extraction and the like. Clinical tests show that compared with a control group and a placebo group, the compound medicine disclosed by the invention can remarkably improve lung function related indexes of patients and reduce the level of inflammatory factors, and a visual simulation scoring method also proves that the compound medicine can effectively relieve symptoms of cough and asthma. The medicine can be used for preparing aerosol inhalation medicines for treating various respiratory diseases such as bronchial asthma and chronic obstructive pulmonary diseases, and has a good application prospect.

The invention discloses a bronchial asthma symptom intelligent monitoring method and system based on multi-source data, and relates to the technical field of artificial intelligence, and the method comprises the steps: obtaining multi-mode asthma data after time-space alignment; performing weighted fusion on the western medicine index, the environment index, the tongue condition index and the pulse condition index by using a preset pathogenesis mapping rule to generate an asthma pathology state vector; inputting the asthma pathology state vector into an emergency response channel, analyzing abnormal change of short-term peak flow velocity, synchronously inputting into a chronic evolution channel to track long-term change of tongue condition and pulse condition, and generating emergency response integral and syndrome integral; and superposing the emergency response integral and the syndrome integral on a time axis, and triggering risk assessment when the emergency response integral and the syndrome integral meet the time condition coincidence and the peak flow rate declines to reach an early warning threshold value. According to the method, asthma pathology state vectors are respectively input into an emergency response channel and a chronic evolution channel, so that synchronous monitoring and dynamic modeling of acute attack and chronic disease courses are realized.

The invention relates to a plant astragalus membranaceus-derived exosome-like nano-vesicle as well as a preparation method and application thereof. The nano-vesicle is prepared by chopping astragalus membranaceus roots, juicing, carrying out differential-ultra-high-speed centrifugation and filtering. The nano vesicle disclosed by the invention has good biocompatibility and immunomodulatory activity, can be used for intervening bronchial asthma, and shows a relatively good treatment effect; the nano-vesicle can be used as a novel natural plant-derived drug delivery system, and the problems of poor stability, single action mechanism, low delivery efficiency and the like of traditional Chinese medicine components are solved.

The invention relates to an exhaled gas metabolism marker for evaluating attack severity of a bronchial asthma patient and a screening method of the exhaled gas metabolism marker. The marker is acetic acid. The screening method of the exhaled gas metabolism marker for evaluating the severity of the attack of the bronchial asthma patients comprises the following steps: respectively collecting exhaled gas of the bronchial asthma patients with mild continuous attack and moderate continuous attack as analysis samples; analyzing each exhaled gas sample by using HPPI-TOFMS to obtain an original mass spectrum of each exhaled gas sample; preprocessing the original mass spectrum of each expired gas sample to obtain data containing relative intensity information of metabolites; carrying out univariate and multivariate analysis on the data containing the relative intensity information of the metabolites, and screening out differential metabolites; a metabolite with the largest difference is screened out through binary logistic regression analysis, and the metabolite is the marker. The method is simple to operate, can efficiently and objectively evaluate the severity of the attack of the bronchial asthma patient, and has important clinical application value.

The present invention discloses a method and system for intelligent monitoring of bronchial asthma symptoms in children based on multi-source data, which relates to the field of medical technology, including obtaining historical physiological monitoring data and historical asthma information, classifying historical physiological monitoring data based on historical asthma information, and obtaining physiological monitoring data classification information. The present invention uses a data deviation evaluation coefficient to screen historical data, obtain baseline physiological parameters, and achieve accurate analysis of children's physiological states, so as to facilitate timely discovery of abnormal physiological data and improve the efficiency of asthma symptom monitoring. Through the environmental impact coefficient, the impact of the environment on physiological data during asthma is accurately analyzed, so as to accurately set the physiological monitoring threshold, ensure the stability and reliability of the monitoring system, and accurately adjust asthma monitoring in abnormal environments through breathing audio data, ensuring a rapid response to asthma symptom warnings.

The present invention discloses the use of SRT2104 in the preparation of a drug for treating bronchial asthma, and relates to the technical field of bronchial asthma treatment. The present invention comprehensively evaluates the activation effect of SRT2104 on airway epithelial SIRT1 and the relief effect on asthmatic airway inflammation under asthma conditions, confirms the effectiveness of SRT2104 in activating airway epithelial SIRT1 and controlling asthmatic airway inflammation under asthma conditions, and lays a foundation for the discovery of clinical medical targets and the development of drugs in the treatment of bronchial asthma.

The present invention discloses a bronchial asthma prediction method and system, which relates to the technical field of asthma prediction, including defining an experimental group and a control group and extracting RNA from the experimental group and the control group for cryopreservation; performing quantitative PCR analysis on the cryopreserved RNA and extracting target cDNA; collecting clinical data of the experimental group and calculating the corresponding biomarker concentration according to the target cDNA; constructing a bronchial asthma prediction model, and outputting the predicted risk probability value of each patient suffering from asthma. By accurately extracting and preserving RNA samples from the experimental group and the control group, combining quantitative PCR analysis to obtain significantly changed gene expression, and further combining with biomarker concentrations, the dynamic monitoring of asthma-related inflammatory reactions is successfully achieved. By constructing a bronchial asthma prediction model, the invention can accurately assess the patient's asthma risk.

The invention discloses a preparation method of a pyridopyrimidine compound and application of the pyridopyrimidine compound in preparation of an asthma medicine. The pyridopyrimidine compound provided by the invention is applied to preparation of medicines for preventing / treating asthma, DPPO is applied to prevention and treatment of bronchial asthma, and a new medicine choice is brought to asthma patients. Experimental results show that the DPPO can obviously inhibit attack of asthma and secretion of related inflammatory factors such as IL-1beta, IL-4, IL-5, IL-6, IL-13 and IL-17A, has a relaxation effect on tracheal smooth muscles, has the effects of resisting angiogenesis, airway remodeling and inflammation, and achieves the effect of treating asthma. In addition, current researches show that the asthma pathogenesis is very complex, DPPO can obviously improve pathological changes of mouse lung tissues sensitized by house dust mite extract (HDM) and toluene diisocynate (TDI), and the DPPO has certain universality and can be speculated to have huge application potential in research and development of drugs for treating various asthma.

The application discloses a bronchial asthma phenotype identification index screening method based on exosomeomics, comprising the following steps: acquiring bronchial asthma medical record data to construct a medical record data subset, and extracting multi-dimensional information to obtain diagnostic characteristics; generating an original feature set by using common diagnostic characteristics of different bronchial asthma phenotypes; constructing a knowledge graph according to exosomeomics related knowledge and the action mechanism of exosomes of different cell sources on bronchial asthma, screening exosome characteristics, and expanding the original feature set; constructing a feature selection task based on multi-objective optimization, obtaining exosome feature combinations of different bronchial asthma on the basis of the common diagnostic characteristics, and determining exosome identification indexes of bronchial asthma phenotypes after comparison and verification of the identification accuracy of the original common diagnostic characteristics. The exosomeomics indexes highly related to bronchial asthma diagnosis are screened, biomarkers are obtained for predicting allergic and asthma conditions, and the identification accuracy of bronchial asthma phenotypes is improved.

The application belongs to the field of biological medicine, and particularly relates to application of DJ-1 in treatment and diagnosis of bronchial asthma. DJ-1 is used as a target in preparation or screening of drugs for bronchial asthma or allergic inflammation; a drug for treating hyperplasia of goblet cells and mucus metaplasia in bronchial asthma, and an animal model for studying inhibition of differentiation of goblet cells and mucus metaplasia. The application identifies, for the first time, an important role of a signal pathway DJ-1 / Ltc4s, which has not been found in eosinophils and lung epithelial cells before, in differentiation of secretory cells into goblet cells, and finds, for the first time, an inhibitory effect of inhibition of the DJ-1 / Ltc4s signal pathway on differentiation of goblet cells in lung epithelial cells through a large number of studies.

The present application relates to the technical field of medical auxiliary, in particular to an environment monitoring and warning device for bronchial asthma patients and a system thereof, which comprises an air path switching module, an environment monitoring module, a lung function monitoring module, a main control module and a warning module. The air path switching module is used for setting a state data threshold, collecting patient state data, judging whether the patient state data exceeds the state data threshold, and adjusting the gas flow direction according to the judgment result; when the patient state data exceeds the state data threshold, the air path switching module is used for guiding the gas exhaled by the patient to the lung function monitoring module. Through the design of the air path switching module, the present application can automatically adjust the gas delivery path according to the current state of the patient, and then coordinate the two operations of environment monitoring and lung function monitoring, and through the comprehensive analysis of the environment data and the lung function data, the influence of the current environment on the patient's breathing can be effectively judged, and then the targeted warning for the patient can be provided.

The invention discloses a bronchial asthma treatment drug based on RBX1 inhibition and application thereof, and finds that expression of RBX1 in asthma patients and disease models is up-regulated, and the expression level of RBX1 is in positive correlation with airway epithelial barrier injury and active oxygen accumulation degree, which indicates that RBX1 is a key new target for asthma treatment. On the basis of the compound Z226407860 and the compound Z4189742053, the condition that the expression of the RBX1 can be effectively inhibited is further proved. In an in-vitro model, the compounds not only significantly reduce the protein level of RBX1, but also show a good synergistic treatment effect: the compounds can effectively relieve the injury of the airway epithelial barrier and promote the integrity recovery of the barrier, and can inhibit the excessive accumulation of active oxygen at the same time, so that the asthma process is intervened from two correlative core pathological links. The research provides a solid experimental basis and a candidate compound with a clear prospect for developing a therapeutic drug which aims at bronchial asthma and has a brand new action mechanism.

According to the traditional Chinese medicine health-care preparation with the blood vessel dredging and multi-effect conditioning functions, 50% of traditional Chinese medicines with homology of medicine and food are combined with other traditional Chinese medicines, so that multi-effect conditioning is achieved, toxic and side effects are small, and the traditional Chinese medicine health-care preparation can be taken for a long time. According to the composition of the preparation, the traditional Chinese medicines for promoting blood circulation to remove meridian obstruction and the traditional Chinese medicines for soothing the nerves and tonifying the brain are scientifically combined together to achieve the effect of mutual enhancement. The preparation is a medicinal liquor, and is convenient to use and scientific in preparation process. The preparation has a powerful blood vessel dredging function; the traditional Chinese medicine composition also has the functions of regulating the antioxidant capacity of cells, removing excessive free radicals, prolonging the apoptosis time, recovering neuronal functions, inhibiting the growth of tumor cells, regulating immunity, supplementing activating factors and the like. The traditional Chinese medicine can be used for preventing and treating hypertension, coronary heart disease, arrhythmia (atrial and ventricular premature beat), rheumatic arthritis, bronchial asthma, malignant tumor, depression, insomnia, senile amnesia, white hair and alopecia; the goals of beautifying, health care and life prolonging are achieved.

The present application discloses a respiratory rehabilitation management system and method for children with bronchial asthma, which uses artificial intelligence-based data information analysis and coding technology to perform physiological state time series correlation on the physiological data of asthmatic children objects, and performs embedded coding and semantic fusion on the personal information of the asthmatic children objects, so as to automatically generate a respiratory rehabilitation training plan based on the cross-modal joint representation between the multi-parameter time series correlation features of children's physical signs and the semantic fusion representation of the personal information of the target object. In this way, it is possible to reveal the trend of changes in physiological indicators over time and consider the relevance to the patient's personal information to generate a more accurate and personalized rehabilitation training plan, so as to better meet the needs of patients of different ages, thus realizing the refined and personalized management of children with bronchial asthma.

The present invention discloses a traditional Chinese medicine composition for treating airway inflammation and a preparation method thereof. The traditional Chinese medicine composition comprises raw materials in the following weight ratios: 32-36 parts of honey-fried ephedra, 6-10 parts of asarum, 32-36 parts of magnolia flower, 6-10 parts of perilla seed, 32-36 parts of stir-fried immature bitter orange with bran, 6-10 parts of semen lepidii, 6-10 parts of loquat leaf, 32-36 parts of wine-processed scutellaria baicalensis, 10-14 parts of semen zanthoxyli, and 6-10 parts of liquorice. The selected raw materials of the traditional Chinese medicine composition conform to the compatibility principle of "sovereign, minister, assistant, and guide". Each component synergistically or jointly functions, so that the traditional Chinese medicine composition has the effects of relieving exterior syndrome and dispersing lung qi, regulating qi and resolving phlegm, relieving cough and asthma. Looking at the whole prescription, the compatibility of various herbs is rigorous and reasonable, closely following the etiology and pathogenesis of asthma, embodying the principle of treating the symptoms first in traditional Chinese medicine, and mainly treating airway inflammations such as cold asthma syndrome, bronchial asthma, and asthmatic bronchitis, and the effect is ideal.

The invention discloses a Xiaoqinglong decoction and Xiaoqinglong granules prepared from kadsura longepedunculata, a bronchial asthma model is established by using a mouse, and the pharmacological action of kadsura longepedunculata on treating bronchial asthma is determined to be superior to that of Similarly, a bronchial asthma model is established by a mouse, and the pharmacological action of the Xiaoqinglong decoction and Xiaoqinglong granules obtained after optimization is superior to that of the original formula. The combined optimization method is also suitable for formula optimization of a classic famous formula containing schisandra chinensis and mainly used for treating bronchial asthma.

The invention relates to the technical field of medicine, in particular to application of kidney tonifying and asthma relieving decoction in treating asthma, and is technically characterized in that according to the scheme, a bronchial asthma kidney qi deficiency syndrome model is established, a pyroptosis path is utilized, and key inflammatory bodies and inflammatory body related cell factors of the pyroptosis are combined, so that the bronchial asthma kidney qi deficiency syndrome model is established. According to the invention, the mechanism of the kidney-tonifying and asthma-relieving decoction for improving asthma symptoms and intervening the development of the disease course is deeply researched, the mechanism of the kidney-tonifying and asthma-relieving decoction for regulating and controlling the pyroptosis of asthma cells and inhibiting the expression of T cell NLRP3, Caspase 1, Gasdermin family and IL-1beta through an STAT6 / GATA-3 pathway so as to improve the airway inflammation of asthma is provided, and the research on the influence of the kidney-tonifying and asthma-relieving decoction on the pyroptosis signal pathway is developed. The invention can provide a scientific basis for the application of the kidney-tonifying and asthma-relieving decoction to the treatment of asthma, further research the effective target of the kidney-tonifying and asthma-relieving decoction on the molecular level and the essential material basis of the kidney qi deficiency syndrome, and provide a theoretical basis and a new thought for revealing the pathogenesis of asthma and research on the essence of the syndrome.

The present invention discloses an application of HFREP1 protein in preparing a kit for diagnosing bronchial asthma. The present invention finds that there is a significant difference in the HFREP1 protein content in the serum of healthy subjects and bronchial asthma patients, and the HFREP1 protein content in the serum of bronchial asthma patients is significantly higher than that of healthy subjects. Further diagnostic efficacy tests show that HFREP1 protein can effectively diagnose and distinguish healthy subjects from bronchial asthma patients with high diagnostic accuracy, and can be used to develop a kit for diagnosing bronchial asthma, which is significantly more objectivity than existing diagnostic methods.

The invention provides a dry powder inhalation preparation taking enoxone as an active ingredient. The preparation is small in particle size, high in lung delivery efficiency, small in dosage and capable of remarkably improving the medication compliance of patients. The dry powder inhalation preparation can significantly reduce the level of white blood cells in pulmonary alveolar lavage fluid of a bronchial asthma rat model, improve the lung function and the lesion degree of trachea, bronchus and lung, and has an obvious treatment effect on bronchial asthma.

To provide a therapeutic agent for asthmatic attacks associated with viral infection, and a prophylactic agent for plastic bronchitis associated with viral or bacterial infection.SOLUTION: A therapeutic agent for asthmatic attacks associated with viral infection or a prophylactic agent for plastic bronchitis associated with viral or bacterial infection is prepared that comprises an antibody that binds to immunoglobulin E (IgE) as an active ingredient. Here, a representative example of the virus is influenza virus (A(H1N1)pdm09).SELECTED DRAWING: Figure 1A

FIELD: pediatrics and pulmonology.SUBSTANCE: used to predict the risk of severe bronchial asthma in children. Anamnesis is collected, blood is taken, and the child's blood is tested in a laboratory. From the anamnesis, the duration of the disease in years and the number of exacerbations over the current 12 months in points are specified. The peak expiratory flow rate is measured using a peak flow meter, %. The concentration of connexin 43 (CX43), ng / ml, is determined in the child’s blood serum at the time of inclusion in the study. The prognosis for the risk of severe bronchial asthma in children P is calculated using the stated formula. If the P value is 0.52 or higher, a high risk of severe bronchial asthma is predicted.EFFECT: method provides the possibility of increasing the accuracy and reliability of the prognosis of the severity of bronchial asthma in children by taking into account the declared clinical symptoms and risk factors for bronchial asthma in children and adolescents of both sexes who do not have signs of a severe course of the disease at the time of examination.1 cl, 4 ex

The invention discloses an expiratory gas metabolite combined marker for diagnosing asthma and a screening method of the expiratory gas metabolite combined marker. The expiratory gas metabolite combined marker for diagnosing asthma consists of dimethylamine and amino styrene. The screening method comprises the following steps: respectively collecting an exhaled gas sample of a healthy person and an exhaled gas sample of an asthma patient; carrying out HPPI-TOFMS detection analysis on the exhaled gas sample to obtain an original fingerprint spectrogram of the metabolic components; the spectrogram data is preprocessed, the obtained data containing metabolite information is sequentially subjected to univariate analysis and multivariate analysis, differential metabolites between the healthy people and the asthma patients are screened out, and the optimal combination of the differential metabolites between the healthy people and the asthma patients is screened out through binary logistic regression analysis, namely the combined marker; the HPPI-TOFMS analysis technology and the metabonomics method are combined to be used for screening the expired gas metabolite combined marker of bronchial asthma for the first time, and the method is easy to operate and has important economic benefits and wide application prospects.

The present invention relates to the prophylactic and / or therapeutic treatment of a disease selected from the group consisting of long-term COVID disease, myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) disease, fibromyalgia, dementia, neoplastic disease, autoimmune disease, schizophrenia, epileptic seizure disease, excessive inflammatory disease, chronic inflammatory bowel disease, rheumatic disease, obesity, and the like. Hyperuricemia, diabetes (IDDM / NIDDM), acute viral diseases, amyotrophic lateral sclerosis (ALS), bronchial asthma, atopic allergic disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, autoimmune diseases / antibody-related diseases, bipolar affective disorders, celiac disease (CD), chronic obstructive pulmonary disease (COPD), and the like. Chronic inflammatory bowel disease (CED) (i.e. Crohn's disease, ulcerative colitis), cystic fibrosis / cystic fibrosis, depression, endometriosis, polycystic ovarian syndrome, eating disorders, anxiety disorders, addiction disorders, frontotemporal dementia (Pickk's disease), Graves's disease (GD), generalized cardiovascular diseases, Alzheimer's disease, Parkinson's disease, meningitis, multiple sclerosis (MS), and the like. Muscular dystrophy, neurodermatitis, peripheral arterial occlusion disease (PAOD), pneumonia, generalized post-vaccination syndrome and vaccine damage, post-viral infection syndrome, psoriasis, pulmonary arterial hypertension, restless leg syndrome, restrictive pulmonary disease, rheumatoid arthritis (RA), division affective disorder, sepsis, sicca syndrome (SS), scleroderma, and the like. Systemic lupus erythematosus (SLE) and unsatisfactory fertility desires, using an active agent having a nicotinic acetylcholinergic agonist and / or an active agent having a muscarinic acetylcholinergic agonist and / or a muscarinic acetylcholinergic antagonist. This provides a very effective prophylactic and / or therapeutic treatment for these diseases. This prevention or treatment is also readily tolerable, cost effective and easy to apply.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and discloses a traditional Chinese medicine composition, a traditional Chinese medicine preparation and a preparation method and application thereof. According to the preparation method, the traditional Chinese medicine composition and the preparation thereof provided by the invention, the extraction transfer rate of active effective components of the prescription medicines is improved; the traditional Chinese medicine composition can be used for reducing body temperature, resisting viruses, and / or treating cold and cough, upper respiratory tract infection, acute and chronic tracheal and bronchitis, pneumonia, bronchial asthma, measles combined pneumonia, children pertussis and / or pungent and cool catharsis, clearing lung and relieving asthma, and relieving cough and reducing phlegm.

A use of SRT2104 in preparation of a drug for treatment of bronchial asthma is provided, relating to the field of bronchial asthma treatment. The comprehensive analysis of the activation effect of SRT2104 on silent information regulator 1 (SIRT1) in the airway epithelium under asthma conditions and its alleviation effect on asthma airway inflammation is conducted. It is demonstrated that SRT2104 can be activated in the airway epithelium under asthma condition and effectively control asthma airway inflammation. A foundation is laid for the discovery of clinical drug targets and the development of drugs for the treatment of bronchial asthma.

The invention discloses a budesonide modified compound, a pharmaceutical composition and application of the budesonide modified compound, the budesonide modified compound is a compound shown in a formula (I) or a salt of the compound shown in the formula (I), deposition of the budesonide modified compound in the oropharynx part and the throat part is little, and therefore adverse reactions can be reduced, and the budesonide modified compound can be used for preparing medicines. The pharmaceutical composition can be used for treating glucocorticoid-dependent or non-dependent bronchial asthma or asthmatic chronic bronchitis, and can be administered through any proper administration route according to clinical requirements.

The invention discloses application of an ENDOU inhibitor in preparation of a medicine for treating airway epithelium inflammation, and belongs to the field of biological medicine. The invention provides application of a reagent for detecting the expression level of ENDOU in preparation of a kit for diagnosing and / or detecting airway epithelium inflammation or bronchial asthma, and further provides application of an ENDOU inhibitor in preparation of a medicine for treating airway epithelium inflammation or bronchial asthma. The invention proves that ENDOU affects LPS-induced inflammatory response by regulating FOXO1 and IL-17A pathways, is a key molecule for regulating airway epithelial inflammation, is expected to become a therapeutic target for airway inflammation, provides a theoretical basis for research of related drug targets, also provides a new pathophysiology mechanism for occurrence of bronchial asthma, and has a broad application prospect. The composition can be used for preventing and treating bronchial asthma.

The utility model relates to the technical field of drug delivery devices, and discloses a drug delivery device for treating children bronchial asthma, which comprises a main body mechanism and a drug delivery mechanism, the drug delivery mechanism is positioned above the main body mechanism, the main body mechanism comprises a drug storage box body, a waterproof shell and a mixing assembly, the waterproof shell is fixedly installed at the left end of the inner end of the pesticide storage box body, and the mixing assembly is located in the pesticide storage box body; and the mixing assembly comprises a mounting bracket and a servo motor, and the mounting bracket is fixedly mounted at the inner end of the waterproof shell. According to the drug delivery device for treating the child bronchial asthma, the main body mechanism is installed, so that the mixing capacity of the drug delivery device is improved, in the actual use process, drugs can be conveniently mixed and stirred according to use requirements, the manual labor amount is reduced, and the use efficiency is improved; and the market competitiveness of the administration device for treating children bronchial asthma is improved.

This invention belongs to the field of traditional Chinese medicine composition technology, specifically relating to a traditional Chinese medicine composition and preparation for treating bronchial asthma. The traditional Chinese medicine composition consists of the following raw materials in parts by weight: 9-11 parts Perilla seed, 6-8 parts White mustard seed, 6-8 parts Lepidium seed, 6-8 parts Radish seed, 4-6 parts Scutellaria baicalensis, 9-11 parts Houttuynia cordata, 3-5 parts Prepared Ephedra, 4-6 parts Fresh Fritillaria cirrhosa, 5-7 parts Magnolia officinalis, and 3-5 parts Schisandra chinensis. This invention not only benefits lung qi and promotes proper lung function, but also addresses the issue that impaired lung function can lead to stagnant heat and dampness. Therefore, Scutellaria baicalensis and Houttuynia cordata are used to clear heat, purge fire, and dry dampness. Persistent wheezing inevitably depletes lung qi, damages lung fluids, and harms kidney essence. Therefore, Schisandra chinensis is used to astringe the lungs, nourish the kidneys, generate fluids, and consolidate essence, restoring normal lung function and benefiting both the lungs and kidneys, thus relieving wheezing.